RxDoctor Payments Data

Ajay Ajmani, MD

Internal Medicine · Sanford, NCNPI 1811998867

Payments from drug & device makers

$6,319in general payments, 2019–2025

Across 355 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$840
  • Amgen$734
  • AstraZeneca$464
  • Johnson & Johnson$454
  • Pfizer$409
  • AbbVie$339
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,18598%
  • Education$1352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,319 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$249,906
Medicare patients
145
Services billed
4,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept41$304,635
Humira PenAdalimumab28$199,894
RemicadeInfliximab17$96,594
EnbrelEtanercept12$92,402
OtezlaApremilast13$62,787
RybelsusSemaglutide55$60,864
Actemra ActpenTocilizumab11$60,013
OzempicSemaglutide42$37,513
EliquisApixaban65$32,716
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl171$19,431
AptiomEslicarbazepine Acetate13$16,557
SuboxoneBuprenorphine Hcl/Naloxone Hcl46$16,506
Spiriva RespimatTiotropium Bromide17$14,497
TrulicityDulaglutide12$12,210
MyrbetriqMirabegron23$10,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$734$155,18925 claims
Johnson & JohnsonRemicade, Xarelto$454$105,76633 claims
Novo NordiskRybelsus, Ozempic$840$98,37697 claims
PfizerEliquis$409$32,71665 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$60$22,82130 claims
Sunovion Pharmaceuticals Inc.Aptiom$59$16,55713 claims
Indivior Inc.Suboxone$317$16,50646 claims
Lilly USA, LLCTrulicity$66$12,21012 claims
AstraZenecaFarxiga, Symbicort$464$10,30525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Sanford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →